{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:07:55Z","timestamp":1791259675115,"version":"4.1.0"},"reference-count":69,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T00:00:00Z","timestamp":1224115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Killer immunoglobulin\u2010like receptor (KIR)\u2010ligand mismatched natural killer (NK) cells play a key role in achieving durable remission after haplo\u2010identical transplantation for acute myeloid leukaemia. We investigated the feasibility of transfusing haplo\u2010identical, T\u2010cell depleted, KIR\u2010ligand mismatched NK cells, after conditioning therapy with melphalan and fludarabine, to patients with advanced multiple myeloma (MM) followed by delayed rescue with autologous stem cells. No graft\u2010versus\u2010host disease or failure of autologous stem cells to engraft was observed. There was significant variation in the number of allo\u2010reactive NK cells transfused. However, all NK products containing allo\u2010reactive NK cells killed the NK cell target K562, the MM cell line U266, and recipient MM cells when available. Post NK cell infusion there was a rise in endogenous interleukin\u201015 accompanied by increasing donor chimaerism. Donor chimaerism was eventually lost, which correlated with the emergence of potent host anti\u2010donor responses indicating that the immunosuppressive properties of the conditioning regimen require further optimization. Further, blocking of inhibitory KIR\u2010ligands with anti\u2010human leucocyte antigen antibody substantially enhanced killing of MM cells thus highlighting the potential for modulating NK\/MM cell interaction. Encouragingly, 50% of patients achieved (near) complete remission. These data set the stage for future studies of KIR\u2010ligand mismatched NK cell therapy in the autologous setting.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07340.x","type":"journal-article","created":{"date-parts":[[2008,10,16]],"date-time":"2008-10-16T06:50:14Z","timestamp":1224139814000},"page":"641-653","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["Infusion of haplo\u2010identical killer immunoglobulin\u2010like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation"],"prefix":"10.1111","volume":"143","author":[{"given":"Jumei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Szmania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun K.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyangi A.","family":"Malaviarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amberly","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ann","family":"Baxter\u2010Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cottler\u2010Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Shaughnessy Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110312"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391702"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.117"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06271.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"2744a","DOI":"10.1182\/blood.V110.11.2744.2744","article-title":"In vitro\u2010expanded NK cells have increased TRAIL and NKG2D expression and enhanced TRAIL\u2010mediated tumor cytotoxicity compared to non\u2010expanded NK cells","volume":"110","author":"Berg M.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3893"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119258"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021127"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036228"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0293"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1197"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3581"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000164500.16052.3C"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0350"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.05.007"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03879.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"2743a","DOI":"10.1182\/blood.V110.11.2743.2743","article-title":"Expanded natural killer cells for cellular therapy of acute myeloid leukemia","volume":"110","author":"Fujisaki H.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.2992"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0091"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.4.1768"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.5118"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4825"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.04.008"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1487"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.7.3415"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05513.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000235859.24513.43"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.644"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.6540"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3031"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04604.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974"},{"key":"e_1_2_7_39_1","first-page":"526a","article-title":"Clinical significance of killer Ig\u2010like receptor (KIR) on acute GvHD, rejection and leukemia relapse in patients transplanted non\u2010T cell depleted marrow from unrelated donors; role of inhibitory KIR epitope matching and activating KIR genotype","volume":"102","author":"Morishima Y.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.12.6640"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri999"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3548"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021847"},{"key":"e_1_2_7_44_1","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka D.","year":"1995","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703411"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405730101"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.1.333.413a31_333_339"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038687"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702685"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4253"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430"},{"key":"e_1_2_7_56_1","doi-asserted-by":"crossref","first-page":"3392a","DOI":"10.1182\/blood.V106.11.3392.3392","article-title":"Stimulation with K562 cells transfected with 4\u20101BBL and IL\u201015 expands and activates natural killer (NK) cells with specific cytotoxicity for multiple myeloma (MM)","volume":"106","author":"Shi J.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078535"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.5.2307"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1841"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng2077"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-4-14"},{"key":"e_1_2_7_62_1","doi-asserted-by":"crossref","first-page":"660a","DOI":"10.1182\/blood.V108.11.660.660","article-title":"CS1 is expressed on myeloma cells from early stage, late stage, and drug\u2010treated multiple myeloma patients, and is selectively targeted by the huluc63 antibody","volume":"108","author":"Szmania S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051725"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4489"},{"key":"e_1_2_7_67_1","doi-asserted-by":"crossref","first-page":"582a","DOI":"10.1182\/blood.V110.11.582.582","article-title":"Anti\u2010KIR (1\u20107F9): a fully human monoclonal antibody (mAb) that blocks KIR2DL1, \u20102 and \u20103, promoting natural killer (NK) cell\u2010mediated lysis of tumor cells in vitro and in vivo","volume":"110","author":"Wagtmann N.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"2741a","DOI":"10.1182\/blood.V110.11.2741.2741","article-title":"Ex vivo expansion of cord blood NK cell have in vivo efficacy against leukemia","volume":"110","author":"Xing D.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704670"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07340.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07340.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:32:58Z","timestamp":1695965578000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07340.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,11]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07340.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07340.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,11]]},"assertion":[{"value":"2008-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}